CRISPR Therapeutics co-founder Emmanuelle Charpentier was among those named as Thomson Reuters Citation Laureates this week, "researchers whose work has achieved quantifiable esteem and impact in the scientific community, at a level far beyond the norm. This attainment, demonstrated in the elevated quantity of highly cited papers written by these select researchers, signals that they are "of Nobel class" and "likely to earn the Nobel someday."